112018-01-6

Basic information

• Product Name: 7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one
• Synonyms: 7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one;RWJ-22867;Bemoradanum;Bemoradanum [inn-latin];Unii-G2S2V1etbq
• CAS NO: 112018-01-6
• Molecular Formula: C13H13 N3 O3
• Molecular Weight: 259.2606
• Mol File: 112018-01-6.mol
• Article Data: 1

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.51g/cm³
• Refractive Index: 1.712
• CAS DataBase Reference: 7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one(112018-01-6)
• EPA Substance Registry System: 7-[(1,4,5,6-Tetrahydro-4-methyl-6-oxopyridazin)-3-yl]-4H-1,4-benzoxazin-3(2H)-one(112018-01-6)

Safety Data

• Hazardous Substances Data: 112018-01-6(Hazardous Substances Data)

Usage

Uses

Cardiotonic.

InChI:InChI=1/C13H13N3O3/c1-7-4-11(17)15-16-13(7)8-2-3-9-10(5-8)19-6-12(18)14-9/h2-3,5,7H,4,6H2,1H3,(H,14,18)(H,15,17)

Upstream product

• 144062-50-0 7-(3-Dimethylamino-2-methyl-propionyl)-4H-benzo[1,4]oxazin-3-one 
• 117278-83-8 3-Methyl-4-oxo-4-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl)-butyronitrile 
• 114603-35-9 3,4-Dihydro-7-(1-oxopropyl)-3-oxo-1,4(2H)-benzoxazine 
• 130521-20-9 3'-amino-4'-hydroxypropiophenone 
• 117278-84-9 4-oxo-4-<3,4-dihydro-3-oxo-1,4(2H)-benzoxazin-7-yl>-3-methylbutyric acid 

Relevant articles and documents

6-Benzoxazinylpyridazin-3-ones: Potent, Long-Acting Positive Inotrope and Peripheral Vasodilator Agents

A series of 6-benzoxazinylpyridazin-3-ones was prepared and evaluated for inhibition of cardiac phosphodiesterase (PDE) fraction III in vitro and for positive inotropic activity in vivo. 6--2,3,4,5-tetrahydro-5-methylpyridazin-3-one (bemoradan) was found to be an extremely potent and selective inhibitor of canine PDE fraction III and a long-acting, potent, orally active inotropic vasodilator agent in various canine models.Additional benzoxazin-6-yl and -8-yl compounds were also prepared.Altering the pyridazinone substitution from the 6-position to the 7-position produced a 14-fold increase in the iv cardiotonic potency (ED50) from 77 to 5.4 μg/kg while substitution at the 8-position reduced potency.Methyl substitution at various sites in the molecule was also examined.Positive inotropic activity was maintained for between 8 and 24 h after a single oral dose (100 μg/kg) of bemoradan in dogs, thus making it one of the most potent and long-acting orally effective inotropes yet described.Bemoradan is currently under development as a cardiotonic agent for use in the management of congestive heart failure.